Picture loading failed.

Anti-LAG3 therapeutic antibody (Pre-made Relatlimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Relatlimab (INN; development code BMS-986016) is a monoclonal antibody designed for the treatment of melanoma.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-476-1mg 1mg 3090
GMP-Bios-ab-476-10mg 10mg 21890
GMP-Bios-ab-476-100mg 100mg 148000
GMP-Bios-ab-476-xmg >100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-LAG3 therapeutic antibody (Pre-made Relatlimab biosimilar,Whole mAb)
INN Name Relatlimab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II/III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2018
Year Recommended2019
CompaniesBristol-Myers Squibb;Ono Pharmaceutical;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Conditions Approvedna
Conditions ActiveMalignant melanoma;Colorectal cancer;Gastric cancer;Renal cell carcinoma;Solid tumours;Oesophageal cancer;Glioblastoma
Conditions DiscontinuedChronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Hodgkin's disease;Mantle-cell lymphoma;Non-Hodgkin's lymphoma
Development Techna